RCC is the most common form of kidney cancer, which is among the 10 most frequently diagnosed cancers in the U.S. annually.
The approval is based on results from CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of Cabometyx and Opdivo compared with sunitinib in previously untreated advanced or metastatic RCC. These results were presented during the European Society of Medical Oncology Virtual Congress 2020 in September.
The FDA reviewed the application for Cabometyx and Opdivo under the Real-Time Oncology Review pilot program and Fast Track designation.
The RTOR pilot program, which allows an applicant to pre-submit components of the application to allow the FDA to review clinical trial data before the complete filing is submitted, aims to explore a more efficient review process to ensure safe and effective treatments are available to patients sooner.
In CheckMate -9ER, the combination regimen significantly improved overall survival compared with sunitinib (HR= 0.60, 98.89% CI 0.40-0.89; p=0.001).
Median OS has not yet been reached in either treatment arm. Median progression-free survival was doubled at 16.6 months for Cabometyx in combination with Opdivo compared with 8.3 months for sunitinib (HR 0.51, 95% CI 0.41-0.64; p
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients